Board of Directors
Shlomo Ben-Haim, MD, D.Sc – Co-Founder
Dr. Ben-Haim is the co-founder of a number of successful medical and biomedical companies in the fields of congestive heart failure, obesity, diabetes, esthetics and cosmetics, anti-viral medications, deep vein thrombosis prevention, therapy for limb ischemia and post-stroke and sports-injury rehabilitation. His formal education is in the fields of nuclear physics, mathematics, biomedical engineering, philosophy and medicine. He has held faculty appointments as a Professor of Medicine, Physiology and Biophysics, at Harvard University and the Technion – Israel Institute of Technology. Dr. Ben-Haim has published over 100 scientific papers in peer-reviewed journals and holds over 200 patents and patent applications.
Glen D Nelson, MD – Vice Chairman of the Board
Dr. Nelson has previously held various management positions in leading medical device companies, including Vice Chairman of Medtronic, Inc. (1988 until retirement in 2002), Member of the Medtronic Board of Directors (1980-2002), Chairman, President and CEO of the Park Nicollet Medical Center, a large multi-specialty group practice, and Chairman of the Board and CEO of American MedCenters, Inc. Dr. Nelson has over 17 years of experience in practicing surgery.
Robert I Griffin, MS – Member of the Board
Mr. Griffin has previously held various management positions in Medtronic, Inc., most recently Executive Vice President, Medtronic Corporation. Prior to that he served as President of Medtronic’s Pacing Business. Mr. Griffin is currently involved in venture capital activities through his entity, BIG Holdings, as well through two other venture capital groups where he serves on the Advisory Board. He holds an MS in Radiological Science from the University of Washington Graduate School, and a B.S. in physics from Willamette University.
Martin Olin– Member of the Board
Mr. Olin has previously held various positions in the corporate finance field. He started as an Auditor with PriceWaterhouse, and later served as Manager at Novo Nordisk A/S (Denmark). He was then moved to the Paris branch of Novo Nordisk where he served as Finance Director for EMEA and was responsible for finances, legal and IT in the region. In the year2000 Mr. Orlin joined SLS Invest serving as Investment Manager and CFO and later as Investment Director. Mr. Olin has broad-based international experience with more than a decade of board work experience and a network made up of strong financial and legal skills and expertise. He currently serves as a Board Member of Light Sciences Oncology Inc., PreciSense A/S, NsGene A/S, Metacure Inc., Cellectricon AB, Gyros AB and Chempilots A/S.
Prof. Harold Lebovitz, MD, FACE– Member of the Board
Dr. Lebovitz has previously served as Chief of the Section of Endocrinology and Diabetes, and Director of the National Institutes of Health (NIH)-sponsored Clinical Research Center at the State University of New York Health Science Center, where he currently serves as a Professor. He also currently serves on the Board of Directors of the American Association of Clinical Endocrinologists (AACE). He is an internationally recognized authority in the field of diabetes and is author or co-author of more than 200 peer-reviewed publications and 100 chapters or books. Dr. Lebovitz received his BSc and MD from the University of Pittsburgh.
Antony Owers, FCA – Managing Director
Mr. Owers was previously with the accounting firm KPMG from in London, São Paulo, Brazil and Curaçao, the latter as a Senior Partner for many years. He has been a Fellow of the Institute of Chartered Accountants in England and Wales since 1980, and has been British consul to the Dutch Caribbean islands since 1997. He is also treasurer of many charitable foundations in the Netherlands Antilles including the Red Cross, International School, National Trust, Consular Corps, Rotary and Uniting for Children.
Dr. Simos Kedikoglou, MD, CFA, MBA – Member of the Board
Dr. Simos Kedikoglou is the President of the MedInvest group. He was previously a Corporate Vice President of Business Development for Boston Scientific with responsibility for acquisitions, licensing and distribution deals in the US, Europe and Asia. Prior to Boston Scientific, Simos was an Associate Partner with McKinsey & Company in the US, focusing on M&A and has advised clients in completed healthcare deals with a combined value of $45 billion. Simos holds a Medical Degree from the University of Athens, Greece, an MBA with distinction and a Master’s in Public Health from Harvard University ,and he is a CFA Charterholder.
